Cardiol Therapeutics (CRDL) vs Journey Medical (DERM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cardiol Therapeutics (CRDL) has outperformed Journey Medical (DERM) over the past year, gaining 24.5% versus a loss of 21.2%. Journey Medical is the larger company by market cap ($170.2 million vs $157.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRDL | DERM |
|---|---|---|
| Share price | $1.30 | $6.03 |
| Market cap | $157.36M | $170.19M |
| 1-day change | -1.89% | +1.34% |
| YTD return | +38.36% | -22.83% |
| 1-year return | +24.53% | -21.19% |
| 5-year return | -66.41% | — |
| EPS (TTM) | $-0.25 | $-0.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.34 | $9.56 |
| 52-week low | $0.88 | $4.31 |
| Distance from 52-week high | -44.66% | -36.89% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +545.56% | +128.03% |
| Average volume | 1.44M | 182.16K |
| Shares outstanding | 121.51M | 22.22M |
| Employees | 18 | 58 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRDL has outperformed DERM by 45.7 percentage points over the past year.
About Cardiol Therapeutics
CRDL stock →Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
About Journey Medical
DERM stock →Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
CRDL vs DERM FAQ
Which is bigger, Cardiol Therapeutics or Journey Medical?
Journey Medical (DERM) is larger, with a market capitalization of $170.19M compared with $157.36M for Cardiol Therapeutics (CRDL).
Which stock has performed better over the past year, CRDL or DERM?
CRDL returned +24.53% over the past 12 months, compared with -21.19% for DERM (price return, excluding dividends). Past performance does not predict future results.
Are Cardiol Therapeutics and Journey Medical in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Cardiol Therapeutics and Biotechnology: Pharmaceutical Preparations for Journey Medical.